drugset / Trial / NCT00299195
A Randomized Study of Sulindac in Oral Premalignant Lesions
Completed
63 enrolled
Memorial Sloan Kettering Cancer Center
AIMS Institute · collabNarayana Hrudayalaya Hospitals · collabRegional Cancer Centre, Trivandrum, India · collabWeill Medical College of Cornell University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in people with arthritis (inflammation of a joint). This study is being done by Memorial Sloan-Kettering Cancer Center in New York, Amrita Institute of Medical Sciences and Research Center in Cochin, India, and Regional Cancer Centre (RCC) in Trivandrum, India.
Timeline
- Start
- 2006-02-23
- Primary completion
- 2020-01-06
- Completion
- 2020-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sulindac | Small molecule | 150 mg | Oral |